Resumen:
Aim Materials and Methods To investigate the impact of renal function on the safety and efficacy of insulin glargine 300 U/mL (Gla-300) and insulin glargine 100 U/mL (Gla-100). A meta-analysis was performed using pooled 6-month data from the EDITION 1, 2 and 3 trials (N = 2496). Eligible participants, aged >= 18 years with a diagnosis of type 2 diabetes (T2DM), were randomized to receive once-daily evening injections of Gla-300 or Gla-100. Pooled results were assessed by two renal function subgroups: estimated glomerular filtration rate (eGFR) Results Conclusions The decrease in glycated haemoglobin (HbA1c) after 6 months and the proportion of individuals with T2DM achieving HbA1c targets were similar in the Gla-300 and Gla-100 groups, for both renal function subgroups. There was a reduced risk of nocturnal (12:00-5:59 am) confirmed (<= 3.9 mmol/L [<= 70 mg/dL]) or severe hypoglycaemia with Gla-300 in both renal function subgroups (eGFR <60 mL/min/1.73 m(2): relative risk [RR] 0.76 [95% confidence interval {CI} 0.62-0.94] and eGFR >= 60 mL/min/1.73 m(2): RR 0.75 [95% CI 0.67-0.85]). For confirmed (<= 70 mg/dL [<= 3.9 mmol/L]) or severe hypoglycaemia at any time of day (24 hours) the hypoglycaemia risk was lower with Gla-300 vs Gla-100 in both the lower (RR 0.94 [95% CI 0.86-1.03]) and higher (RR 0.90 [95% CI 0.85-0.95]) eGFR subgroups. Gla-300 provided similar glycaemic control to Gla-100, while indicating a reduced overall risk of confirmed (<= 3.9 and <3.0 mmol/L [<= 70 and <54 mg/dL]) or severe hypoglycaemia, with no significant difference between renal function subgroups.
